Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Santarus Shares Soar on Court Ruling

By Pharmaceutical Processing | September 5, 2012

SAN DIEGO (AP) — Santarus Inc. said Tuesday that a federal appeals court partly reversed a lower court’s decision that some of the patents supporting Santarus’ acid reflux drug Zegerid were not valid.

Santarus shares climbed more than 14 percent in the regular session and kept going in after-hours trading.

The company said the U.S. Court of Appeals for the Federal Circuit reversed in part a 2010 district court ruling that some of the claims supporting two patents on Zegerid were not valid. The case will be returned to the U.S. District Court for the District of Delaware to hear further arguments based on the ruling. Santarus said it wants to stop Par Pharmaceutical Cos. from selling a generic version of Zegerid and seek damages from Par.

Shares of Santarus climbed 88 cents, or 14.2 percent, to $7.05 on Tuesday.

Santarus sued Par Pharmaceutical in 2007 over Par’s proposed generic version of Zegerid. Par began selling a generic version of Zegerid capsules in July 2010, after the Delaware district court overturned some of the Zegerid patents. Santarus said the patents that are in dispute cover both capsule and powder versions of Zegerid, or omeprazole. It said those patents don’t expire until July 2016, and Par was found to have infringed on them.

Santarus’ other products include the diabetes drugs Glumetza and Cycloset and the cholesterol drug Fenoglide.

Santarus shares rose 88 cents, or 14.2 percent, to close at $7.06. they added another 20 cents, or 2.8 percent, in after-hours trading.

 

 

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards